Novo Nordisk's (NVO) weight-loss drug Wegovy is being offered in smaller doses of a compounded version by online weight-loss tool Noom, Reuters reported Tuesday, citing senior company officials.

Noom's compounded semaglutide, the active ingredient in Wegovy, is being offered as part of a program personalized for patients, the report said.

Noom Chief Executive Geoff Cook said the move would not conflict with US regulations amid a crackdown on mass production of generic versions of Wegovy, the report said.

"There is a personalized, and there has always been a personalized, exception," Cook said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)